[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=Branch1][C][=O][C@H1][C][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring1][N][C][C][C@H1][C@H1][Ring1][=Branch1][C][C][C@@H1][C@@][Ring1][=Branch1][Branch1][=N][C][C][C@@][Branch1][Ring2][C][Ring1][=Branch1][Branch1][C][C][O][C][C]"}, {"from": "gpt", "value": "The molecule is the 3\u03b2-methylated synthetic analog of [allopregnanolone], a metabolite of [progesterone]. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABAA receptors to enhance their inhibitory effects, and are thus known to have anxiolytic, analgesic, anticonvulsant, sedative, hypnotic, and anesthetic properties.  Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABAA receptors. It was approved by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment indicated specifically for CDD."}]